The interactions of aurein 1.2 with cancer cell membranes

Biophysical Chemistry

Volumn 127, Issue 1-2, 2007, Pages 78-83

  Dennison, Sarah R ^a   Harris, Frederick ^a   Phoenix, David A ^a  

^a UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

Author keywords

Anionic lipid; Aurein 1.2; Lysine residues; Snorkelling; T98G cancer cell membranes

Indexed keywords

ANION; LIPID; MEMBRANE LIPID; PEPTIDE; PROTEIN AUREIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL LINE; CELL MEMBRANE; GLIOBLASTOMA; HUMAN; HUMAN CELL; MONOLAYER CULTURE; PRIORITY JOURNAL; PROTEIN INTERACTION;

ANTIMICROBIAL CATIONIC PEPTIDES; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MEMBRANE; GLIOBLASTOMA; HUMANS; MEMBRANE LIPIDS; PROTEIN CONFORMATION;

EID: 33847175151     PISSN: 03014622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpc.2006.12.009     Document Type: Article

References (39)

1. Boyle P., and Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann. Oncol. 16 (2005) 481-488
2. Parkin D.M. International variation. Oncogene 23 (2004) 6329-6340
3. Kovvali G., Shiff S., Telang N., Das K., Kohgo Y., Narayan S., and Li H. Carcinogenesis: The more we seek to know the more we need to know - challenges in the post Genomic Era. J. Carcinog. 2 (2003) 1-2
4. Sarasin A. An overview of the mechanisms of mutagenesis and carcinogenesis. Mutat. Res. 544 (2003) 99-106
5. Gonzalez-Nicolini V., and Fussenegger M. In vitro assays for anticancer drug discovery - a novel approach based on engineered mammalian cell lines. Anticancer Drugs 16 (2005) 223-228
6. Jaracz S., Chen J., Kuznetsova L.V., and Ojima I. Recent advances in tumor-targeting anticancer drug conjugates. Bioorg. Med. Chem. 13 (2005) 5043-5054
7. Leslie E.M., Deeley R.G., and Cole S.P. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. 204 (2005) 216-237
8. Takara K., Sakaeda T., and Okumura K. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr. Pharm. Des. 12 (2006) 273-286
9. Cross S.S. The molecular pathology of new anti-cancer agents. Curr. Diagn. Pathol. 11 (2005) 329-339
10. Breedveld P., Beijnen J.H., and Schellens J.H. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol. Sci. 27 (2006) 17-24
11. Chen H., Xu Z., Peng L., Fang X., Yin X., Xu N., and Cen P. Recent advances in the research and development of human defensins. Peptides 27 (2006) 931-940
12. Sheppard G.S., and Bouska J.J. Why optimize cancer drugs for ADMET?. Drug Discov. Today Ther. Strateg. 2 (2005) 343-349
13. Leuschner C., and Hansel W. Membrane disrupting lytic peptides for cancer treatments. Curr. Pharm. Des. 10 (2004) 2299-2310
14. Papo N., and Shai Y. Host defense peptides as new weapons in cancer treatment. Cell. Mol. Life Sci. 62 (2005) 784-790
15. Brown K.L., and Hancock R.E. Cationic host defense (antimicrobial) peptides. Curr. Opin. Immunol. 18 (2006) 24-30
16. Bulet P., Stocklin R., and Menin L. Anti-microbial peptides: from invertebrates to vertebrates. Immunol. Rev. 198 (2004) 169-184
17. Dennison S.R., Wallace J., Harris F., and Phoenix D.A. Amphiphilic alpha-helical antimicrobial peptides and their structure/function relationships. Protein Pept. Lett. 12 (2005) 31-39
18. Papagianni M. Ribosomally synthesized peptides with antimicrobial properties: biosynthesis, structure, function, and applications. Biotechnol. Adv. 21 (2003) 465-499
19. Dennison S.R., Whittaker M., Harris F., and Phoenix D.A. Anticancer α-helical peptides and structure/function relationships underpinning their interactions with tumour cell membranes. Curr. Protein Pept. Sci. 7 (2006) 487-500
20. Apponyi M.A., Pukala T.L., Brinkworth C.S., Maselli V.M., Bowie J.H., Tyler M.J., Booker G.W., Wallace J.C., Carver J.A., and Separovic F. Host-defence peptides of Australian anurans: structure, mechanism of action and evolutionary significance. Peptides 25 (2004) 1035-1054
21. Doyle J., Llewellyn L.E., Brinkworth C.S., Bowie J.H., Wegener K.L., Rozek T., Wabnitz P.A., Wallace J.C., and Tyler M.J. Amphibian peptides that inhibit neuronal nitric oxide synthase. Isolation of lesuerin from the skin secretion of the Australian Stony Creek frog Litoria lesueuri. Eur. J. Biochem. 269 (2002) 100-109
22. Marcotte I., Wegener K.L., Lam Y.H., Chia B.C., de Planque M.R., Bowie J.H., Auger M., and Separovic F. Interaction of antimicrobial peptides from Australian amphibians with lipid membranes. Chem. Phys. Lipids 122 (2003) 107-120
23. Rozek T., Bowie J.H., Wallace J.C., and Tyler M.J. The antibiotic and anticancer active aurein peptides from the Australian Bell Frogs Litoria aurea and Litoria raniformis. Part 2. Sequence determination using electrospray mass spectrometry. Rapid Commun. Mass Spectrom. 14 (2000) 2002-2011
24. Rozek T., Wegener K.L., Bowie J.H., Olver I.N., Carver J.A., Wallace J.C., and Tyler M.J. The antibiotic and anticancer active aurein peptides from the Australian Bell Frogs Litoria aurea and Litoria raniformis the solution structure of aurein 1.2. Eur. J. Biochem. 267 (2000) 5330-5341
25. Bligh E.G., and Dyer W.J. A rapid method of total lipid extraction and purification. Can. J. Med. Sci. 37 (1959) 911-917
26. Hardy N.J., Richardson T.H., and Grunfeld F. Minimising monolayer collapse on Langmuir troughs. Colloids Surf., A Physicochem. Eng. Asp. 284-285 (2006) 202-206
27. Brandenburg K., Harris F., Dennison S., Seydel U., and Phoenix D. Domain V of m-calpain shows the potential to form an oblique-orientated alpha-helix, which may modulate the enzyme's activity via interactions with anionic lipid. Eur. J. Biochem. 269 (2002) 5414-5422
28. Demel R.A. Model membrane monolayers-description of use and interaction. Methods Enzymol. 32 (1974) 539-545
29. Ambroggio E.E., Separovic F., Bowie J.H., Fidelio G.D., and Bagatolli L.A. Direct visualization of membrane leakage induced by the antibiotic peptides: maculatin, citropin, and aurein. Biophys. J. 89 (2005) 1874-1881
30. Balla M.S., Bowie J.H., and Separovic F. Solid-state NMR study of antimicrobial peptides from Australian frogs in phospholipid membranes. Eur. Biophys J. 33 (2004) 109-116
31. Dennison S.R., Harris F., and Phoenix D.A. Are oblique orientated alpha-helices used by antimicrobial peptides for membrane invasion?. Protein Pept. Lett. 12 (2005) 27-29
32. Harris F., Brandenburg K., Seydel U., and Phoenix D. Investigations into the mechanisms used by the C-terminal anchors of Escherichia coli penicillin-binding proteins 4, 5, 6 and 6b for membrane interaction. Eur. J. Biochem. 269 (2002) 5821-5829
33. Harris F., Demel R., de Kruijff B., and Phoenix D.A. An investigation into the lipid interactions of peptides corresponding to the C-terminal anchoring domains of Escherichia coli penicillin-binding proteins 4, 5 and 6. Biochim. Biophys. Acta 1415 (1998) 10-22
34. Bauer R., and Dicks L.M. Mode of action of lipid II-targeting lantibiotics. Int. J. Food Microbiol. 101 (2005) 201-216
35. Johnsen L., Fimland G., and Nissen-Meyer J. The C-terminal domain of pediocin-like antimicrobial peptides (class IIa bacteriocins) is involved in specific recognition of the C terminal part of cognate immunity proteins and in determining the antimicrobial spectrum. J. Biol. Chem. 280 (2005) 9243-9250
36. Ran S., Downes A., and Thorpe P.E. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res. 62 (2002) 6132-6140
37. Utsugi T., Schroit A.J., Connor J., Bucana C.D., and Fidler I.J. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res. 51 (1991) 3062-3066
38. Segrest J.P., Jones M.K., De Loof H., Brouillette C.G., Venkatachalapathi Y.V., and Anantharamaiah G.M. The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. J. Lipid Res. 33 (1992) 141-166
39. Hattori T., Andoh T., Sakai N., Yamada H., Kameyama Y., Ohki K., and Nozawa Y. Membrane phospholipid composition and membrane fluidity of human brain tumour: a spin label study. Neurol. Res. 9 (1987) 38-43